Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

AstraZeneca : European Medicines Agency Recommends Asthma Treatment Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 01:23pm CEST

By Adam Clark

AstraZeneca PLC (AZN.LN) said Friday that the European Medicines Agency has recommended the marketing authorization of its benralizumab drug for asthma treatment.

The pharmaceutical company said the recommendation is based on phase 3 clinical trial data and is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients.

The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The drug is also under regulatory review in the U.S., Japan and several other countries.

Shares are down 54 pence, or 1.1%, at 4908 pence at 1203 GMT.

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
08:35aAstraZeneca Reports Positive Lynparza Trial Results
DJ
08:15aASTRAZENECA : to present new data demonstrating breadth of research portfolio in..
PU
08:01aASTRAZENECA : Lynparza shows 70% reduction in PFS ovarian cancer
AQ
10/21ASTRAZENECA : SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy c..
PU
10/21ASTRAZENECA : Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy C..
BU
10/19ASTRAZENECA : CHMP issues a positive opinion for Bevespi Aerosphere for the trea..
AQ
10/19ASTRAZENECA : New data on mechanisms of acquired resistance after 1st-line Tagri..
PU
10/19ASTRAZENECA : Bevespi Aerosphere Gets EU Marketing Recommendation
DJ
10/19ASTRAZENECA : CHMP issues a positive opinion for Bevespi Aerosphere for the trea..
PU
10/19ASTRAZENECA : CHMP positive opinion Bevespi Aerosphere
PU
More news
News from SeekingAlpha
10/20Ibrance + Faslodex extends survival in late-stage breast cancer study 
10/19AstraZeneca launches new study to investigate lung cancer resistance mechanis.. 
10/19European advisory group backs six new meds 
10/17Johnson & Johnson suspends clinical development of antiviral lumicitabine 
10/16AstraZeneca's Lynparza an Orphan Drug in U.S. for pancreatic cancer 
Financials ($)
Sales 2018 22 357 M
EBIT 2018 5 470 M
Net income 2018 2 276 M
Debt 2018 14 730 M
Yield 2018 3,52%
P/E ratio 2018 42,31
P/E ratio 2019 35,66
EV / Sales 2018 5,05x
EV / Sales 2019 4,77x
Capitalization 98 249 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,4 $
Spread / Average Target 1,0%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.72%97 642
JOHNSON & JOHNSON-4.19%374 244
PFIZER20.87%257 933
NOVARTIS0.07%220 104
ROCHE HOLDING LTD.-4.56%206 610
MERCK AND COMPANY23.44%192 044